ArticleOncology letters2025
Distinguishing acute leukemia subtypes: The role of hsa_circ_0012152 and hsa_circ_0020093 in peripheral blood.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute leukemia (AL), a rapidly progressing hematological malignancy originating from the bone marrow, is primarily subclassified into acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL). Obtaining bone marrow samples can be challenging due to a number of reasons, including dilution or inaccessibility. Therefore, the present study focused on identifying novel diagnostic biomarkers in the peripheral blood for AL subgroups. Circular RNAs (circRNAs) are non-coding RNA molecules associated with various diseases. In the present study, to validate the distinct circRNA expression patterns distinguishing AML from ALL in peripheral blood, reverse transcription-quantitative polymerase chain reaction was employed. The diagnostic accuracy of hsa_circ_0020093 and hsa_circ_0012152 was then assessed using receiver operating characteristic curve analysis, and hsa_circ_0020093 was selected for further exploration using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. The findings revealed that the expression patterns of hsa_circ_0020093 and hsa_circ_0012152 clearly differentiated ALL from AML in peripheral blood. The potential target genes of hsa_circ_0020093 identified were associated with critical biological processes such as protein serine kinase activity and cadherin binding. Furthermore, these genes are involved in signaling pathways including MAPK and mTOR. We propose that hsa_circ_0020093 plays a crucial role in initiating and promoting ALL by modulating downstream target genes through either hsa-microRNA (miR)-153-3p or hsa-miR-194-5p. The results of the present study demonstrate that hsa_circ_0020093 and hsa_circ_0012152 hold significant promise as diagnostic biomarkers for subclassifying AL into ALL or AML in peripheral blood. This discovery lays the foundation for future research endeavors aimed at elucidating the role of circRNAs in the pathogenesis and treatment of AL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.